Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00780507 · ClinicalTrials.gov registry record

Fecal Biomarker Study for Patients With Ulcerative Colitis

A clinical trial of Ulcerative Colitis, sponsored by Warner Chilcott.

Completed
Registry status
89
Enrollment target
20
Study locations

NCT00780507 is a study of Ulcerative Colitis that has completed, run by Warner Chilcott. The registered enrollment target is 89 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00780507, a study of Ulcerative Colitis, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
89 participants
Enrollment target
20
Study locations

Study Summary

The present study will analyze fecal levels of FC and FL in UC patients who relapse (flare) while on a QD or a BID Asacol treatment regimen and compare those levels to levels of FC and FL in UC patients who do not relapse (flare).

Conditions Studied

Study Locations (20)

California

  • Research Facility - Anaheim
  • Research Facility - Folsom
  • Research Facility - Los Angeles
  • Research Facility - Merced
  • Research Facility - San Diego
  • Research Facility - Upland

Florida

  • Research Facility - Fort Lauderdale
  • Research Facility - New Port Richey
  • Research Facility - Palm Harbor
  • Research Facility - Tampa
  • Research Facility - Zephyrhills

Georgia

  • Research Facility - Decatur
  • Research Facility - Marietta
  • Research Facility - Newnan

Illinois

  • Research Facility - Arlington Heights
  • Research Facility - Oak Lawn
  • Research Facility - Urbana

Arkansas

  • Research Facility - Lowell

Colorado

  • Research Facility - Lafayette

Connecticut

  • Research Facility - Torrington

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2007-08
Est. Completion 2009-07

Sponsor

Warner Chilcott

53 total trials

What the Registry Record Tells You About NCT00780507

The ClinicalTrials.gov registry entry for NCT00780507 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (96% lower). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.

NCT00780507 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00780507 about?

NCT00780507 is a clinical study titled "Fecal Biomarker Study for Patients With Ulcerative Colitis". The present study will analyze fecal levels of FC and FL in UC patients who relapse (flare) while on a QD or a BID Asacol treatment regimen and compare those levels to levels of FC and FL in UC patients who do not relapse (flare).

What is the current status of trial NCT00780507?

This trial is currently completed. The enrollment target is 89 participants. The study started on 2007-08. Estimated completion is 2009-07.

What conditions does trial NCT00780507 study?

This clinical trial studies the following conditions: Ulcerative Colitis.

Who is sponsoring clinical trial NCT00780507?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00780507 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.